Trading Signals: ALT Stock Price Prediction and Forecast (Thu. Oct. 6, 2005 - Fri. Oct. 27, 2023)(Altimmune, Inc. )
| ALT latest price $405.0000 (6.3%) ($363.0000 - $405.0000) on Mon. Aug. 13, 2012. | |
| | Trend Analysis and Forecast | | | | Average Daily Percentage Swing | 5.27% (three month average) | | RSI | 43 | | Latest Price | $405.0000(6.3%) | | Stocks Behave Similarly | Similar Stock List | | Daily Trend | ALT declines -0.7% a day on average for past five trading days. | | Weekly Trend | ALT declines -2.7% a week on average for past two weeks. | | Market Behavior | Normal for large cap. Normal for small cap. | | Correlated ETFs | Broad market will support ALT advance at 0% a week (0% probability)
EWI(4%) EWP(4%) FXI(4%) EEM(3%) EWG(3%) | | Factors Impacting ALT price | ALT will decline at least -2.635% in a week (0% probabilities).
TLT(-3%) SHY(-2%) REMX(-1%) LQD(-1%) TIP(-0%) | | | | | | | | Relative Volatility | (options are extremely cheap) | | | | | Market Trend Strength | -2.635% (StdDev 5.27%) | | Hourly BBV | 0 () | | Intraday Trend | 8.9% | | | | | |
|
| Resistance Level | $432.04 | | 5 Day Moving Average | $411(-1.46%) | | 10 Day Moving Average | $411.7(-1.63%) | | 20 Day Moving Average | $432.04(-6.26%) | | To recent high | -17.7% | | To recent low | 12.5% | | Market Cap | $15.614b | | | | | | |
Altimmune, Inc. is a clinical stage immunotherapeutic biotechnology company. It focuses on the discovery and development of products to stimulate robust and durable immune responses for the prevention and treatment of diseases. The company's portfolio includes RespirVec and Densigen that targets to stimulate the elements of the human immune system to treat respiratory diseases, chronic infections, and cancer. Altimmune was founded in 1997 and is headquartered in Gaithersburg, MD.June 01, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has authorized the Company to proceed with a clinical trial of T-COVID, an investigational agent for the treatment of early COVID-19. Patient enrollment in the Phase 1/2 clinical trial is expected to commence in June, with data readout anticipated in Q4 2020. |